超大分割放疗用于不利中危和高危前列腺癌安全有效:II期试验5年结果
这项II期试验评估8次超大分割放疗(UHRT)治疗前列腺癌的毒性和生化无病生存(BDFS),2012-2017年入组154例,其中92例为不利中危或高危。全组5年BDFS为94.3%,不利中危/高危组为90%,5年晚期泌尿/肠道2级及以上毒性为17.8%/7.4%,无4-5级毒性。
要点
- 8次UHRT方案对不利中危/高危前列腺癌安全可行。
- 全组5年BDFS 94.3%,不利中危/高危组90%。
- 5年晚期泌尿/肠道2级+毒性17.8%/7.4%,无4-5级毒性。
核心结论
- 8次UHRT方案可安全用于不利中危/高危前列腺癌患者,复发率与EBRT联合近距离放疗相近但毒性更轻。
研究设计与样本
- II期试验,2012-2017年纳入154例前列腺癌患者,其中92例为不利中危或高危,接受螺旋断层放疗43.8-45.2 Gy/8次/3周。
- 73%接受激素治疗,其中51%为新辅助。
主要发现
- 中位随访48个月(范围19-84)。
- 全组粗BDFS和5年BDFS分别为97.4%和94.3%。
- 不利中危/高危组粗BDFS和5年BDFS分别为96.7%和90%,粗无转移生存率为98%。
- 全组5年累积泌尿/肠道2级及以上晚期毒性分别为17.8%和7.4%,无4-5级毒性,1例晚期3级泌尿毒性。
临床怎么用
- 对于不利中危/高危前列腺癌,可考虑8次UHRT作为安全有效的治疗选择,但需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report toxicity (primary endpoint) and biochemical disease-free survival (BDFS) outcomes of a phase II trial evaluating ultra-hypofractionated radiation therapy (UHRT), focusing on patients with unfavourable intermediate-risk and high-risk prostate cancer (PCa). PATIENTS AND METHODS: From 2012 to 2017, 154 patients (92 with unfavourable intermediate-risk or high-risk PCa) were treated with helical TomoTherapy delivering 43.8-45.2 Gy in eight fractions over 3 weeks. Of these, 73% received hormonotherapy (51% neoadjuvant). RESULTS: The median (range) follow-up was 48 (19-84) months. For the whole series, crude BDFS and 5-year BDFS rates were 97.4% and 94.3%, respectively. The corresponding figures for unfavourable intermediate-risk and high-risk PCa were 96.7% and 90%, respectively. The crude metastasis-free survival rate was 98% for the unfavourable intermediate-risk and high-risk group. For the whole series, the 5-year cumulative urinary/intestinal grade 2+ late toxicity was 17.8/7.4%. No grade 4-5 toxicity was observed. One patient experienced late grade 3 toxicity (urinary). CONCLUSION: This eight-fraction UHRT regimen can be safely delivered to patients with unfavourable intermediate-risk/high-risk PCa. Its relapse rates are similar to those reported for the combination of external beam radiotherapy plus brachytherapy, however, the observed toxicity profile is milder. The disease survival rates compare favourably with historical controls in some other forms of radiotherapy, with similar side effects. Since the low rate of biochemical/metastasis relapse is encouraging, further research to confirm these results is justified.
引用
- Macias VA, Barrera-Mellado I. Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial. BJU Int. 2019. PMID: 31614071. doi:10.1111/bju.14925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。